Impact of retinal fluid-free months on outcomes in nAMD: a treatment agnostic analysis of the HAWK and HARRIER studies.
Sign Up to like & getrecommendations! Published in 2022 at "Retina"
DOI: 10.1097/iae.0000000000003699
Abstract: PURPOSE To assess the effect of the total number of fluid-free months after loading on visual and anatomical outcomes in neovascular age-related macular degeneration (nAMD) patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy. METHODS This… read more here.
Keywords: hawk harrier; fluid free; outcomes namd; retinal fluid ... See more keywords
Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials
Sign Up to like & getrecommendations! Published in 2022 at "Ophthalmologica"
DOI: 10.1159/000524096
Abstract: Introduction: Neovascular age-related macular degeneration (nAMD) is characterized by exudation of fluid from abnormally growing blood vessels in the macula. Anti-vascular endothelial growth factor (VEGF) therapy is standard treatment for nAMD. Fluid resolution is used… read more here.
Keywords: hawk harrier; versus aflibercept; brolucizumab versus; hawk ... See more keywords